For US Healthcare Professionals Only
For US Healthcare Professionals Only
The resources on this page offer information and insights about Jakafi® (ruxolitinib) and treatment of patients with cGVHD who have had an inadequate response to steroids or are steroid refractory/dependent. Be sure to check back regularly as new materials will be added as they become available.
How I Treat: When to Intervene With Jakafi® (ruxolitinib) in Patients With Chronic GVHD
Karolina Faysman, MSN, AOCNP
GVHD Expert
How I Treat: Why we Intervene With Jakafi® (ruxolitinib) at First Signs of Initial Systemic Treatment Failure in Chronic Graft-Versus-Host Disease
Preet M. Chaudhary, MD, PhD
GVHD Expert
cGVHD=chronic graft-versus-host disease.
Indications and Usage
Jakafi® (ruxolitinib) is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.
Jakafi is indicated for treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.
Jakafi is indicated for treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in adult and pediatric patients 12 years and older.
Jakafi is indicated for treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
Important Safety Information
Please see Full Prescribing Information for Jakafi.
Indications and Usage
Jakafi® (ruxolitinib) is indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.
Jakafi is indicated for treatment of intermediate or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.
Jakafi is indicated for treatment of steroid-refractory acute graft-versus-host disease (aGVHD) in adult and pediatric patients 12 years and older.
Jakafi is indicated for treatment of chronic graft-versus-host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
Important Safety Information
Please see Full Prescribing Information for Jakafi.